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Abstract
Background: Glucocorticoids such as prednisolone and dexamethasone are critical drugs used in multi-agent
chemotherapy protocols used to treat acute lymphoblastic leukemia (ALL), and response to glucocorticoids is
highly predictive of outcome. The NOD/SCID xenograft mouse model of ALL is a clinically relevant model in which
the mice develop a systemic leukemia which retains the fundamental biological characteristics of the original
disease. Here we report a study evaluating the NOD/SCID xenograft mouse model to investigate glucocorticoid-
induced gene expression. Cells from a glucocorticoid-sensitive xenograft derived from a child with B-cell precursor
ALL were inoculated into NOD/SCID mice. When highly engrafted the mice were randomized into groups of 4 to
receive dexamethasone 15 mg/kg by intraperitoneal injection or vehicle control. Leukemia cells were harvested
from mice spleens at 0, 8, 24 or 48 hours thereafter, and gene expression analyzed on Illumina WG-6_V3 chips,
comparing all groups to time 0 hours.
Results: The 8 hour dexamethasone-treated timepoint had the highest number of significantly differentially
expressed genes, with fewer observed at the 24 and 48 hour timepoints, and with minimal changes seen across
the time-matched controls. When compared to publicly available datasets of glucocorticoid-induced gene
expression from an in vitro cell line study and from an in vivo study of patients with ALL, at the level of pathways,
expression changes in the 8 hour xenograft samples showed a similar response to patients treated with
glucocorticoids. Replicate analysis revealed that at the 8 hour timepoint, a dataset with high signal and differential
expression, using data from 3 replicates instead of 4 resulted in excellent recovery scores of > 0.9. However at
other timepoints with less signal very poor recovery scores were obtained with 3 replicates.
Conclusions: The NOD/SCID xenograft mouse model provides a reproducible experimental system in which to
investigate clinically-relevant mechanisms of drug-induced gene regulation in ALL; the 8 hour timepoint provides
the highest number of significantly differentially expressed genes; time-matched controls are redundant and
excellent recovery scores can be obtained with 3 replicates.
Background
Glucocorticoids such as prednisolone and dexametha-
sone are critical components of multi-agent chemother-
apy protocols used in the treatment of acute
lymphoblastic leukemia (ALL) [1] due to their ability to
induce apoptosis in lymphoid cells. Despite their use for
over 50 years their mechanism of action is not comple-
tely understood. Glucocorticoids are steroid hormones
that act on target cells through interaction with a speci-
fic glucocorticoid receptor (GR) [2]. The GR is held in a
cytosolic complex by a number of co-chaperone mole-
cules including HSP-90 and HSP-70 [3], and on ligand
binding dissociates from the co-chaperone complex,
dimerizes and is transported to the nucleus where it
binds to palindromic DNA sequences known as
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promoter regions of target genes [4]. This leads to the
activation of transcription of primary target genes,
repression of transcription through interaction with
negative GREs [5] or of gene activation through tran-
scription factors such as AP-1 and NF-ΚB[ 6 ] .I nl y m -
phoid cells, this results in repression of cell cycle
progression through cyclin-D3 and C-MYC [7], and cell
death through the activation of apoptosis. Glucocorti-
coids also induce other non-apoptotic mechanisms of
programmed cell death including autophagy [8] and
mediate a number of pathways involved in the metabo-
lism of carbohydrates, lipids and proteins.
A number of studies have published microarray data of
glucocorticoid-induced genes in lymphoid cells, but com-
parison of the data is complicated by technical differences
in platform and chip type. Previous studies of glucocorti-
coid-induced genes in ALL have been carried out using in
vitro cell-line models [9-15] and patient-derived cells, both
in vivo [16] and in vitro [17]. Cell lines are extensively
used in the study of ALL but in the process of immortali-
zation acquire multiple genetic defects, particularly in the
p53 pathway [18], and mechanisms demonstrated in cell
lines are often not replicated in more clinically relevant
models. Primary patient cells have a finite supply and
rarely survive ex vivo for more than a few days. The non-
obese diabetic/severe combined immunodeficient (NOD/
SCID) xenograft mouse model is widely used to study
ALL. In this model, human leukemia cells obtained from
diagnostic bone marrow biopsies are inoculated into
NOD/SCID mice, and on engraftment establish a systemic
leukemia which retains the fundamental biological charac-
teristics of the original disease [19]. It has also been shown
that the in vivo responses to chemotherapeutic agents,
including dexamethasone, correlates with patient outcome
[20], and thus the NOD/SCID xenograft mouse model
provides a stable, reproducible and clinically relevant
model with which to study ALL. Here we report the first
study investigating glucocorticoid-induced gene expression
in ALL using the NOD/SCID xenograft model, the opti-
mal experimental design, and a comparison of our micro-
array data to publicly available datasets of glucocorticoid-
induced genes in other experimental models.
Methods
NOD/SCID xenograft mouse model
All experimental studies were approved by the Human
Research Ethics Committee and the Animal Care and
Ethics Committee of the University of New South
Wales. ALL-3, a glucocorticoid-sensitive xenograft
derived from a 12 year old girl with mixed lineage leu-
kemia (MLL)-rearranged BCP-ALL, was chosen for this
study. Although MLL-rearranged ALL is associated with
a poor prednisolone response and an inferior outcome
[21], this patient is currently a long-term survivor. ALL-
3d e m o n s t r a t e sin vitro glucocorticoid sensitivity, with
an IC50 of 9.4 nM on exposure to dexamethasone. In
the in vivo NOD/SCID xenograft mouse model, ALL-3
is highly responsive to 4 weeks of treatment with single
agent dexamethasone, with rapid clearance of leukemic
blasts from the peripheral blood and recurrence of leu-
kemia delayed by 63.4 days compared to vehicle-treated
controls [20].
Cells from ALL-3 were inoculated by tail-vein injec-
tion into 28 NOD/SCID mice. The mice were bled
weekly and the samples stained with fluorescein isothio-
cyanate (FITC)-conjugated anti-murine CD45 and allo-
phycocyanin (APC)-conjugated anti-human CD45
(BioLegend, San Diego, CA). Following lysis of erythro-
cytes with FACS lysing solution (BD Biosciences, San
Jose, CA), samples were analyzed by multiparametric
flow cytometry on a FACSCanto cytometer (BD Bios-
ciences, San Jose, CA). Engraftment was calculated as
the proportion of human versus total CD45
+ cells.
When high level (> 70%) engraftment was achieved in
the peripheral blood, between 8 and 10 weeks post-
transplantation, the mice were randomized and split
into groups of 4 to receive either dexamethasone 15
mg/kg (Sigma-Aldrich, St Louis, MO) or vehicle control
by intraperitoneal injectio n .M i c ew e r ec u l l e db yC O 2
asphyxiation at 0 hours (pre-treatment, group 1), 8
hours (groups 2 and 3), 24 hours (groups 4 and 5) or 48
hours (groups 6 and 7) following treatment. The mice
in groups 6 and 7 received a second dose of dexametha-
sone or vehicle control at 24 hours. Two mice suc-
cumbed early to thymoma, a well-recognized
complication in NOD/SCID mice, resulting in 3 mice in
each of groups 6 and 7. Cell suspensions of spleens
were prepared and mononuclear cells enriched and pur-
ified to > 97% human by density gradient centrifugation
using LymphoPrep (Axis-Shield, Norway), and cell viabi-
lity assessed by trypan blue exclusion. RNA was
extracted using the RNeasy mini kit (Qiagen, Hilden,
Germany) and the RNA integrity verified (Agilent Bioa-
nalyzer, Santa Clara, CA). The RNA was amplified using
the Illumina TotalPrep RNA amplification kit (Ambion,
Austin, TX) and hybridized onto Illumina WG-6_V3
chips (Illumina, San Diego, CA). The chips were
scanned on the Illumina Bead Array Reader (Illumina,
San Diego, CA) and gene expression analyzed. The data
have been deposited in NCBI’s Gene Expression Omni-
bus [22] and are accessible through GEO Series acces-
sion number GSE30392 http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE30392.
Gene expression and functional analysis
The sample probe profiles with no normalization or
background correction were exported from BeadStudio
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pre-processed using variance stabilizing transformation
[23] and robust spline normalization in lumi [24] which
takes advantage of each probe being represented by >
25 beads. Differential gene expression was determined
using limma [25] by comparing all treated groups to
time 0 hours, with the positive False Discovery Rate cor-
rection for multiple testing [26]. Complete linkage hier-
archical clustering using Euclidian distance was used to
compare groups to each other. Functional analysis was
performed using gene set enrichment analysis (GSEA)
version 2.04 [27], comparing the limma moderated t-sta-
tistic for each probe in a pre-ranked file, against the
c2_all collection of gene sets from the Molecular Signa-
tures Database [27] version 2.5 with 1000 permutations.
The similarity of the top 100 up- and down-regulated
genesets was assessed using meta-GSEA (Cowley et al,
manuscript in preparation).
Comparison of models
The molecular response to glucocorticoids in xenografts
was compared to publicly available microarray data
[13,16] using parametric analysis of gene set enrichment
[28] implemented in the PGSEA package (version 1.20.1,
Furge and Dykema) from the Bioconductor project [29],
with some modifications to the algorithm to assess sig-
nificance of the genes that are in the geneset and repre-
sented on the microarray, and to allow more control
over control sample specification (available upon
request). Expression levels of each gene in each sample
were converted to expression ratios relative to patient
matched controls before glucocorticoid treatment
(Schmidt et al), time-matched controls (Rainer et al), or
time 0 hours (xenografts). Within each dataset, these
gene-level ratios were summarized into geneset-level Z-
scores, using PGSEA with genesets from the c2_all col-
lection [27]. The Z-scores from each sample from the 3
studies were combined and then compared by hierarchi-
cal clustering of the top 100 gene sets demonstrating
the greatest variance across the combined studies.
Replicate analysis
The stability of results when reducing the number of
replicates was assessed using the Recovery Score method
[30] from the GeneSelector package (version 1.4.0) of
the Bioconductor project [29].
Results and Discussion
It has been demonstrated that changes in gene expression
can be detected as early as 6 hours after treatment of
ALL with glucocorticoids in vivo [16] and in vitro [11],
although earlier timepoints show few, if any, significantly
differentially expressed genes [17]. In this study the 8
hour dexamethasone-treated timepoint demonstrated the
highest number of differentially expressed genes com-
pared to baseline control, with far fewer observed at the
24 and 48 hour dexamethasone-treated timepoints
(Tables 1 and 2, and Figure 1). Whilst a similar propor-
tion of up- and down-regulated genes were identified at
the 8 hour dexamethasone-treated timepoint (1158 vs
1072 respectively, FDR < 0.05), of those with large fold
changes (FC > 2 or FC < 0.5, red dots in Figure 1A), 75%
were up regulated (199 vs 65 respectively), consistent
with the predominant role of glucocorticoids as tran-
scriptional activators. The large numbers of statistically
differentially expressed genes (FDR < 0.05) with small
fold changes (0.5 < FC < 2) are indicative of both small
measurement error across replicates, and thus the high
reproducibility of the xenograft model, and good experi-
mental power resulting from using 4 replicates. There
was minimal significant differential gene expression
across the time-matched controls (Tables 1 and 2). This
demonstrates that in the xenograft mouse model, the 8
hour timepoint provides the greatest information, and
that these changes are not sustained over later time-
points. The handling of the mice and intraperitoneal
vehicle control injections had minimal effect on gene
expression, and thus time-matched controls are
redundant.
At the 8 hour timepoint, there were 173 genes upre-
gulated with a t-statistic (the ratio of fold change to
standard error) > 10 and 25 genes downregulated with a
t-statistic < -10 (corresponding to P < 1.74 × 10
-9 and
FDR < 2.95 × 10
-7,t a b l e3 ) .N o n eo ft h e s eg e n e sh a d
sustained expression changes at 24 or 48 hours, and
although this could potentially reflect the early death of
sensitive cells, there was no significant difference in the
total number of cells harvested from the spleens at any
timepoint compared to the time-matched controls (data
not shown), and all harvests had a cell viability of ≥
96%.
The most significantly differentially expressed gene at
the 8 hour dexamethasone-treated timepoint was
ZBTB16, a known transcriptional repressor and gluco-
corticoid response gene, which has been shown to
Table 1 Number of differentially expressed genes by
False Discovery Rate (FDR), compared to time 0 hours
Timepoint (hours) FDR < 0.25 FDR < 0.1 FDR < 0.05
+-+-+-
Dex 8 2313 2434 1470 1423 1158 1072
Dex 24 970 1087 273 421 75 195
Dex 48 321 327 41 95 12 44
Con 8 000000
Con 24 010101
Con 48 010101
+ upregulated; - downregulated; Dex, dexamethasone-treated; and Con,
control
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[31]. Other known glucocorticoid response genes upre-
gulated included TSC22D3 [32] and SOCS1 [15], both
downstream targets of the glucocorticoid receptor,
FKBP5 [33], a co-chaperone of the glucocorticoid recep-
tor, and MAP kinases 5, 6 and 8 [34]. Downregulated
genes at 8 hours included BCL-2 [35] and C-MYC [36],
both previously described, but also HSP90B1,ag l u c o -
corticoid receptor co-chaperone and regulator of apop-
tosis. The only pro-apoptotic gene consistently
upregulated across multiple microarray analyses is the
BH3-only BCL-2 family member BIM, and it has been
shown that BIM has a critical role in glucocorticoid sen-
sitivity and resistance [37], although in this current
study BIM was only induced 1.3 fold. Thus these genes
identified are consistent with previous reports of
glucocorticoid-induced genes in ALL. Within these
experimental systems however there are significant
potential differences in glucocorticoid exposure between
in vitro and in vivo models - a crucial one is that cells
in vitro are continuously exposed to glucocorticoid
whereas in in vivo models the glucocorticoid is subject
to pharmacokinetic and pharmacodynamic changes
which more accurately reflect changes in patients.
At the later timepoints, significant differential gene
expression was much less marked and predominantly
downregulated. At 24 hours 5 genes were upregulated
(t-statistic > 6) and 10 genes downregulated (t-statistic <
-6, table 4), and at 48 hours 1 gene was upregulated (t-
statistic > 6) and 15 genes downregulated (t-statistic <
-6, table 5). At 24 hours, upregulated genes included
NFKBIA, an inhibitor of NF-ΚB, and TRIM74,w h i c h
was sustained at 48 hours, the significance of which is
uncertain. Downregulated genes were those involved in
cell cycle progression, including CCNF at 24 hours, and
CCNF, CDC20 and AURKA at 48 hours, consistent with
growth arrest.
Functional analysis using GSEA and meta-GSEA on
the expression profiles obtained at 8 hours and 24 hours
after dexamethasone treatment (additional files 1 and 2),
revealed a significant upregulation of metabolic path-
ways, particularly adipogenesis at 8 hours, and a marked
effect on pathways associated with cell cycling and pro-
liferation, particularly downregulation of C-MYC at 8
hours and NF-ΚB at 24 hours, and upregulation of
Figure 1 Volcano plots of significantly differentially expressed genes following treatment with dexamethasone at 8 hours (A), 24
hours (B), 48 hours (C). Significance was defined as log2 Fold Change > 1 or < -1 with False Discovery Rate (FDR) < 0.05. Each dot represents
a single gene, and significant genes indicated by red dots.
Table 2 Number of differentially expressed genes by Fold
Change (FC), compared to time 0 hours
Timepoint (hours) FC > 1.5 FC > 2 FC > 4
+-+ - + -
Dex 8 501 429 201 68 38 0
Dex 24 137 341 15 90 0 0
Dex 48 79 234 5 69 0 3
Con 8 13 71200
Con 24 150 0 0 0
Con 48 73 40200
+ upregulated; - downregulated; Dex, dexamethasone-treated; and Con,
control
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ProbeSet ID Gene t P FDR Definition
Upregulated
ILMN_5080450 ZBTB16 83.77 < 2.2E-16 < 2.2E-16 zinc finger and BTB domain containing 16
ILMN_3800088 MMP7 53.22 < 2.2E-16 < 2.2E-16 matrix metallopeptidase 7
ILMN_1770593 CH25H 53.14 < 2.2E-16 < 2.2E-16 cholesterol 25-hydroxylase
ILMN_6560328 C6orf85 44.60 < 2.2E-16 < 2.2E-16 chromosome 6 open reading frame 85
ILMN_7570561 TSC22D3 39.16 < 2.2E-16 < 2.2E-16 TSC22 domain family, member 3
ILMN_580187 PDE8B 33.88 < 2.2E-16 3.90E-16 phosphodiesterase 8B
ILMN_5130066 C8orf61 33.82 < 2.2E-16 3.90E-16 chromosome 8 open reading frame 61
ILMN_4120431 TMEM100 31.38 < 2.2E-16 1.64E-15 transmembrane protein 100
ILMN_650553 BIN1 29.76 < 2.2E-16 4.43E-15 bridging integrator 1
ILMN_1400373 SLA 29.57 < 2.2E-16 4.63E-15 Src-like-adaptor
ILMN_6330593 PTHR1 29.28 < 2.2E-16 5.22E-15 parathyroid hormone receptor 1
ILMN_6110037 LILRA3 29.04 < 2.2E-16 5.75E-15 leukocyte immunoglobulin-like receptor subfamily A, member 3
ILMN_4150477 LOXL4 28.67 < 2.2E-16 6.66E-15 lysyl oxidase-like 4
ILMN_2680079 OGFRL1 28.65 < 2.2E-16 6.66E-15 opioid growth factor receptor-like 1
ILMN_4210411 NDRG2 28.20 < 2.2E-16 8.62E-15 NDRG family member 2
ILMN_3780093 LILRA1 27.86 < 2.2E-16 1.05E-14 leukocyte immunoglobulin-like receptor subfamily A, member 1
ILMN_240441 IL1R2 27.46 < 2.2E-16 1.33E-14 interleukin 1 receptor, type II
ILMN_4730315 MERTK 26.14 < 2.2E-16 3.31E-14 c-mer proto-oncogene tyrosine kinase
ILMN_3800538 ACPL2 25.90 < 2.2E-16 3.72E-14 acid phosphatase-like 2
ILMN_6860392 UGT2B17 25.83 < 2.2E-16 3.72E-14 UDP glucuronosyltransferase 2 family, polypeptide B17
ILMN_4730541 SLC44A1 25.82 < 2.2E-16 3.72E-14 solute carrier family 44, member 1
ILMN_4860546 CTHRC1 25.64 < 2.2E-16 4.10E-14 collagen triple helix repeat containing 1
ILMN_3460270 ZHX3 24.56 < 2.2E-16 8.79E-14 zinc fingers and homeoboxes 3
ILMN_10639 RASSF4 23.21 < 2.2E-16 2.57E-13 Ras association (RalGDS/AF-6) domain family 4
ILMN_1190064 UGT2B7 23.13 < 2.2E-16 2.67E-13 UDP glucuronosyltransferase 2 family, polypeptide B7
ILMN_6400603 MGC2463 23.06 < 2.2E-16 2.71E-13 poliovirus receptor related immunoglobulin domain containing
ILMN_3450187 IRGM 23.04 < 2.2E-16 2.71E-13 immunity-related GTPase family, M
ILMN_6620528 MT1X 22.95 2.40E-16 2.85E-13 metallothionein 1X
ILMN_1260341 IL13RA1 22.47 3.67E-16 4.13E-13 interleukin 13 receptor, alpha 1
ILMN_2650112 SLC16A2 22.25 4.48E-16 4.91E-13 solute carrier family 16, member 2
ILMN_5570170 PNMT 22.01 5.59E-16 5.95E-13 phenylethanolamine N-methyltransferase
ILMN_870376 C9orf152 21.93 6.02E-16 6.25E-13 chromosome 9 open reading frame 152
ILMN_3190379 TGFBR3 21.52 8.78E-16 8.89E-13 transforming growth factor, beta receptor III
ILMN_1780142 DSCR1 21.08 1.33E-15 1.31E-12 Down syndrome critical region gene 1
ILMN_2640341 FKBP5 20.63 2.05E-15 1.89E-12 FK506 binding protein 5
ILMN_7610136 LOC652626 20.43 2.48E-15 2.23E-12 Leukocyte immunoglobulin-like receptor subfamily B member 2
ILMN_1410609 CORO2A 20.34 2.72E-15 2.35E-12 coronin, actin binding protein, 2A
ILMN_1780088 TBXA2R 20.29 2.84E-15 2.40E-12 thromboxane A2 receptor
ILMN_270431 BAALC 20.23 3.02E-15 2.50E-12 brain and acute leukemia, cytoplasmic
ILMN_6280176 GBE1 20.02 3.72E-15 3.01E-12 glucan (1,4-alpha-), branching enzyme 1
ILMN_6060113 TBX15 19.81 4.62E-15 3.67E-12 T-box 15
ILMN_4890743 IQSEC1 19.71 5.09E-15 3.97E-12 IQ motif and Sec7 domain 1
ILMN_150056 DPEP1 19.65 5.41E-15 4.13E-12 dipeptidase 1
ILMN_2060364 BTNL9 19.26 8.04E-15 5.91E-12 butyrophilin-like 9
ILMN_3830735 UPB1 19.23 8.30E-15 5.91E-12 ureidopropionase, beta
ILMN_5670377 STYK1 19.15 9.09E-15 6.35E-12 serine/threonine/tyrosine kinase 1
ILMN_4390630 STAG3 18.72 1.42E-14 9.39E-12 stromal antigen 3
ILMN_4070048 NPHP4 18.44 1.91E-14 1.25E-11 nephronophthisis 4
ILMN_4220474 C6orf81 18.31 2.16E-14 1.39E-11 chromosome 6 open reading frame 81
ILMN_1470746 PTPN3 18.30 2.23E-14 1.41E-11 protein tyrosine phosphatase, non-receptor type 3
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ILMN_5860576 C20orf133 18.25 2.36E-14 1.47E-11 MACRO domain containing 2
ILMN_6020468 PPP1R14A 18.18 2.52E-14 1.55E-11 protein phosphatase 1, regulatory (inhibitor) subunit 14A
ILMN_1400634 MT1M 18.10 2.76E-14 1.64E-11 metallothionein 1M
ILMN_4250315 ITGA9 17.90 3.46E-14 2.03E-11 integrin, alpha 9
ILMN_5080471 MAP3K6 17.40 6.02E-14 3.44E-11 mitogen-activated protein kinase 6
ILMN_5360242 FLJ42461 17.36 6.28E-14 3.53E-11 smoothelin-like 2
ILMN_6620402 NUDT16 17.33 6.50E-14 3.60E-11 nudix (nucleoside diphosphate linked moiety X)-type motif 16
ILMN_3360112 TMEM2 17.26 7.04E-14 3.85E-11 transmembrane protein 2
ILMN_6840743 PER1 17.22 7.41E-14 3.99E-11 period homolog 1
ILMN_4220347 LRRC1 17.12 8.29E-14 4.33E-11 leucine rich repeat containing 1
ILMN_4850592 P2RY14 17.11 8.35E-14 4.33E-11 purinergic receptor P2Y, G-protein coupled, 14
ILMN_6560300 SLC31A2 16.91 1.05E-13 5.39E-11 solute carrier family 31 member 2
ILMN_4060091 DKFZ 16.87 1.11E-13 5.62E-11 DKFZp451A211 protein
ILMN_6770370 LOC92196 16.28 2.23E-13 1.11E-10 death associated protein-like 1
ILMN_580487 IL9R 16.21 2.40E-13 1.18E-10 interleukin 9 receptor
ILMN_1990300 SOCS1 16.18 2.49E-13 1.21E-10 suppressor of cytokine signaling 1
ILMN_5720424 NRP1 16.17 2.54E-13 1.22E-10 neuropilin 1
ILMN_4180427 CIB4 16.11 2.74E-13 1.30E-10 calcium and integrin binding family member 4
ILMN_4180544 ROPN1L 16.08 2.81E-13 1.32E-10 ropporin 1-like
ILMN_4250167 SOX13 16.04 2.95E-13 1.37E-10 SRY (sex determining region Y)-box 13
ILMN_6330170 CHKA 15.81 3.94E-13 1.81E-10 choline kinase alpha, 3
ILMN_4560192 SFXN5 15.62 4.95E-13 2.25E-10 sideroflexin 5
ILMN_2810136 CAPN11 15.56 5.33E-13 2.40E-10 calpain 11
ILMN_2690709 VIPR1 15.38 6.68E-13 2.91E-10 vasoactive intestinal peptide receptor 1
ILMN_630091 NCOA7 15.38 6.69E-13 2.91E-10 nuclear receptor coactivator 7
ILMN_5390730 MGC17330 15.21 8.25E-13 3.55E-10 phosphoinositide-3-kinase interacting protein 1
ILMN_130364 MST150 15.19 8.49E-13 3.62E-10 MSTP150
ILMN_3450241 KIAA0774 14.95 1.16E-12 4.77E-10 KIAA0774
ILMN_2230678 ACACB 14.80 1.41E-12 5.76E-10 acetyl-Coenzyme A carboxylase beta
ILMN_5870307 LOC440359 14.78 1.44E-12 5.83E-10 similar to muscle Y-box protein YB2
ILMN_3840554 SPOCK2 14.76 1.49E-12 5.95E-10 sparc/osteonectin, cwcv and kazal-like domains 2
ILMN_5810600 MAP3K5 14.69 1.63E-12 6.47E-10 mitogen-activated protein kinase 5
ILMN_2360719 IRAK3 14.65 1.71E-12 6.65E-10 interleukin-1 receptor-associated kinase 3
ILMN_1510121 MTSS1 14.64 1.73E-12 6.66E-10 metastasis suppressor 1
ILMN_540671 LILRB2 14.54 1.98E-12 7.41E-10 leukocyte immunoglobulin-like receptor subfamily B, member 2
ILMN_6980377 MTMR15 14.44 2.26E-12 8.39E-10 myotubularin related protein 15
ILMN_6220288 PRDM1 14.43 2.28E-12 8.39E-10 PR domain containing 1, with ZNF domain
ILMN_7330739 NDRG4 14.42 2.30E-12 8.39E-10 NDRG family member 4
ILMN_2600470 WDR60 14.20 3.10E-12 1.12E-09 WD repeat domain 60
ILMN_4050441 SH3MD4 14.16 3.27E-12 1.17E-09 SH3 multiple domains 4
ILMN_6760546 TIPARP 13.89 4.74E-12 1.64E-09 TCDD-inducible poly(ADP-ribose) polymerase
ILMN_2760537 MTE 13.89 4.75E-12 1.64E-09 metallothionein E
ILMN_160019 SORT1 13.79 5.44E-12 1.83E-09 sortilin 1
ILMN_6330132 ISG20 13.60 7.00E-12 2.32E-09 interferon stimulated exonuclease gene 20 kDa
ILMN_1510685 DOK4 13.52 7.86E-12 2.58E-09 docking protein 4
ILMN_1240228 PAG1 13.47 8.50E-12 2.77E-09 phosphoprotein associated glycosphingolipid microdomains 1
ILMN_580592 CPNE8 13.32 1.04E-11 3.31E-09 copine VIII
ILMN_5870301 KIAA0513 13.32 1.05E-11 3.31E-09 KIAA0513
ILMN_20129 CD52 13.32 1.05E-11 3.31E-09 CD52 molecule
ILMN_1820386 PARVB 13.31 1.06E-11 3.31E-09 parvin, beta
ILMN_6200402 MT1A 13.24 1.17E-11 3.64E-09 metallothionein 1A
ILMN_290661 CLN8 13.10 1.43E-11 4.36E-09 ceroid-lipofuscinosis, neuronal 8
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ILMN_670082 GNA12 13.08 1.47E-11 4.43E-09 guanine nucleotide binding protein (G protein) alpha 12
ILMN_5570286 TACC2 12.99 1.67E-11 5.00E-09 transforming, acidic coiled-coil containing protein 2
ILMN_3190411 STARD13 12.93 1.81E-11 5.32E-09 START domain containing 13
ILMN_4540138 NGB 12.92 1.85E-11 5.39E-09 neuroglobin
ILMN_2000646 B4GALT4 12.83 2.10E-11 6.07E-09 UDP-galactosyltransferase, polypeptide 4
ILMN_7100731 CYGB 12.81 2.17E-11 6.17E-09 cytoglobin
ILMN_7050113 NTRK1 12.71 2.52E-11 7.09E-09 neurotrophic tyrosine kinase receptor, type 1
ILMN_2490670 GNPTAB 12.66 2.71E-11 7.52E-09 N-acetylglucosamine-1-phosphate transferase, alpha and beta
ILMN_20170 ZNF385 12.48 3.55E-11 9.72E-09 zinc finger protein 385
ILMN_2630687 CHPT1 12.43 3.80E-11 1.02E-08 choline phosphotransferase 1
ILMN_4120215 WASF2 12.43 3.81E-11 1.02E-08 WAS protein family, member 2
ILMN_5260494 TMLHE 12.39 4.06E-11 1.08E-08 trimethyllysine hydroxylase, epsilon
ILMN_5220333 C14orf139 12.31 4.54E-11 1.20E-08 chromosome 14 open reading frame 139
ILMN_3850440 FCER1G 12.12 6.07E-11 1.60E-08 Fc fragment of IgE, receptor for; gamma polypeptide
ILMN_1030008 TGFB3 12.11 6.21E-11 1.63E-08 transforming growth factor, beta 3
ILMN_1450468 MYT1 12.02 7.04E-11 1.81E-08 myelin transcription factor 1
ILMN_7560541 SLC2A5 12.01 7.19E-11 1.83E-08 solute carrier family 2 member 5
ILMN_2030438 GBA2 12.01 7.21E-11 1.83E-08 glucosidase, beta (bile acid) 2
ILMN_6840328 SMAD3 12.00 7.35E-11 1.86E-08 SMAD family member 3
ILMN_3930390 SMAP1L 11.91 8.40E-11 2.11E-08 stromal membrane-associated protein 1-like
ILMN_7570196 TSPAN9 11.90 8.54E-11 2.12E-08 tetraspanin 9
ILMN_6980546 CACNA1I 11.90 8.56E-11 2.12E-08 calcium channel, voltage-dependent, T type, alpha 1I subunit
ILMN_1710364 LCN6 11.89 8.72E-11 2.15E-08 lipocalin 6
ILMN_5360424 RPS6KA2 11.77 1.04E-10 2.54E-08 ribosomal protein S6 kinase, 90 kDa, polypeptide 2
ILMN_5890193 MS4A4A 11.72 1.14E-10 2.75E-08 membrane-spanning 4-domains, subfamily A, member 4
ILMN_3390292 KLF9 11.66 1.24E-10 2.98E-08 Kruppel-like factor 9
ILMN_5720059 GFOD1 11.65 1.26E-10 3.02E-08 glucose-fructose oxidoreductase domain containing 1
ILMN_7650523 TMEM46 11.57 1.43E-10 3.39E-08 transmembrane protein 46
ILMN_5700392 LOC654000 11.46 1.70E-10 3.95E-08 ribosome biogenesis protein BMS1 homolog 2
ILMN_4810348 C1orf188 11.40 1.88E-10 4.33E-08 chromosome 1 open reading frame 188
ILMN_4280180 CHRNA3 11.39 1.91E-10 4.37E-08 cholinergic receptor, nicotinic, alpha 3
ILMN_270458 CRISPLD1 11.37 1.96E-10 4.45E-08 cysteine-rich secretory protein LCCL domain containing 1
ILMN_450615 MT2A 11.37 1.97E-10 4.46E-08 metallothionein 2A
ILMN_20470 GRASP 11.35 2.02E-10 4.51E-08 GRP1-associated scaffold protein
ILMN_3370594 LILRA2 11.35 2.03E-10 4.51E-08 leukocyte immunoglobulin-like receptor subfamily A, member 2
ILMN_5220397 RREB1 11.34 2.05E-10 4.53E-08 ras responsive element binding protein 1
ILMN_1410192 TDRD9 11.34 2.07E-10 4.56E-08 tudor domain containing 9
ILMN_4070259 LOC653133 11.27 2.30E-10 4.99E-08 guanine nucleotide binding protein (G protein) alpha 12
ILMN_5960682 RBPMS2 11.24 2.41E-10 5.21E-08 RNA binding protein with multiple splicing 2
ILMN_1440300 SLC27A3 11.22 2.50E-10 5.37E-08 solute carrier family 27, member 3
ILMN_5050768 LONRF1 11.20 2.58E-10 5.53E-08 LON peptidase N-terminal domain and ring finger 1
ILMN_6270273 KHDRBS3 11.18 2.67E-10 5.68E-08 KH domain, RNA binding, signal transduction associated 3
ILMN_7100603 KCNK3 11.17 2.70E-10 5.72E-08 potassium channel, subfamily K, member 3
ILMN_2320129 CSDA 11.03 3.38E-10 7.08E-08 cold shock domain protein A
ILMN_3930022 LOC644739 10.99 3.63E-10 7.54E-08 Wiskott-Aldrich syndrome protein family member 4
ILMN_7400133 CUGBP2 10.90 4.20E-10 8.63E-08 CUG triplet repeat, RNA binding protein 2
ILMN_3290301 FZD8 10.88 4.33E-10 8.76E-08 frizzled homolog 8
ILMN_7320520 MTUS1 10.88 4.33E-10 8.76E-08 mitochondrial tumor suppressor 1
ILMN_3780053 PALLD 10.82 4.79E-10 9.60E-08 palladin, cytoskeletal associated protein
ILMN_6860162 LOC441019 10.74 5.49E-10 1.09E-07 hypothetical LOC441019
ILMN_5810154 ALOX15B 10.74 5.50E-10 1.09E-07 arachidonate 15-lipoxygenase, type B
ILMN_3930736 CHST3 10.73 5.59E-10 1.09E-07 carbohydrate (chondroitin 6) sulfotransferase 3
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Page 7 of 13apoptotic pathways at 24 hours. Glucocorticoids are
known to have effects on multiple cellular metabolic
pathways, including glucose and carbohydrate metabo-
lism, and have pro-adipogenic effects [38]. Suppression
of C-MYC is a critical step prior to the initiation of
apoptosis by dexamethasone in ALL [39] and suppres-
sion of NF-ΚB has been described [40].
To determine whether the molecular response to glu-
cocorticoids in this xenograft model of ALL mimicked
the effects seen in either glucocorticoid-treated patients
Table 3 Genes regulated 8 hours following dexamethasone treatment (Continued)
ILMN_60470 STX11 10.72 5.68E-10 1.10E-07 syntaxin 11
ILMN_3390484 SERINC2 10.69 5.95E-10 1.15E-07 serine incorporator 2
ILMN_1430647 TAX1BP3 10.61 6.82E-10 1.31E-07 Tax1 (human T-cell leukemia virus type I) binding protein 3
ILMN_5960440 VDR 10.60 6.99E-10 1.34E-07 vitamin D (1,25-dihydroxyvitamin D3) receptor
ILMN_6290735 EPHB3 10.51 8.10E-10 1.53E-07 EPH receptor B3
ILMN_2680372 SH2D4A 10.46 8.78E-10 1.64E-07 SH2 domain containing 4A
ILMN_2480050 SOX7 10.44 9.13E-10 1.69E-07 SRY (sex determining region Y)-box 7
ILMN_130128 LOC285016 10.41 9.61E-10 1.76E-07 hypothetical protein LOC285016
ILMN_4890451 GRAMD3 10.39 9.87E-10 1.80E-07 GRAM domain containing 3
ILMN_770161 C10orf73 10.39 9.92E-10 1.81E-07 chromosome 10 open reading frame 73
ILMN_2450202 KIF3C 10.35 1.05E-09 1.88E-07 kinesin family member 3C
ILMN_6840468 HAL 10.35 1.06E-09 1.89E-07 histidine ammonia-lyase
ILMN_2470070 TBL1X 10.30 1.15E-09 2.04E-07 transducin (beta)-like 1X-linked
ILMN_2320114 KLF13 10.27 1.22E-09 2.15E-07 Kruppel-like factor 13
ILMN_6380112 DIP 10.23 1.31E-09 2.27E-07 death-inducing-protein
ILMN_2470358 IFNGR1 10.22 1.32E-09 2.30E-07 interferon gamma receptor 1
ILMN_4250735 IL27RA 10.07 1.70E-09 2.91E-07 interleukin 27 receptor, alpha
ILMN_1470215 MAP3K8 10.07 1.72E-09 2.91E-07 mitogen-activated protein kinase 8
ILMN_2940373 TACC1 10.06 1.74E-09 2.94E-07 transforming, acidic coiled-coil containing protein 1
Downregulated
ILMN_770538 LYSMD2 -15.49 5.81E-13 2.58E-10 LysM, putative peptidoglycan-binding, domain containing 2
ILMN_7150059 STAMBPL1 -14.61 1.79E-12 6.84E-10 STAM binding protein-like 1
ILMN_5340692 STRBP -14.56 1.93E-12 7.31E-10 spermatid perinuclear RNA binding protein
ILMN_4210397 GLDC -14.05 3.80E-12 1.34E-09 glycine dehydrogenase
ILMN_6980327 DKC1 -13.79 5.44E-12 1.83E-09 dyskeratosis congenita 1, dyskerin
ILMN_50086 TCF12 -13.23 1.19E-11 3.69E-09 transcription factor 12
ILMN_4860356 BYSL -12.81 2.17E-11 6.17E-09 bystin-like
ILMN_4280228 IVNS1ABP -12.70 2.55E-11 7.12E-09 influenza virus NS1A binding protein
ILMN_1990379 SLFN11 -11.82 9.63E-11 2.36E-08 schlafen family member 11
ILMN_5220338 MPEG1 -11.64 1.27E-10 3.03E-08 macrophage expressed gene 1
ILMN_450168 SFRS7 -11.50 1.60E-10 3.74E-08 splicing factor, arginine/serine-rich 7, 35 kDa
ILMN_3460687 KIAA0690 -11.42 1.81E-10 4.19E-08 ribosomal RNA processing 12 homolog
ILMN_3400360 MAPRE2 -11.36 1.99E-10 4.48E-08 microtubule-associated protein, RP/EB family, member 2
ILMN_4010414 PPFIBP1 -11.12 2.92E-10 6.16E-08 PTPRF interacting protein, binding protein 1 (liprin beta 1)
ILMN_1190139 UGT3A2 -10.99 3.61E-10 7.54E-08 UDP glycosyltransferase 3 family, polypeptide A2
ILMN_4150201 BCL2 -10.93 3.99E-10 8.24E-08 B-cell CLL/lymphoma 2
ILMN_780240 C12orf24 -10.85 4.53E-10 9.13E-08 chromosome 12 open reading frame 24
ILMN_6760167 MARCH3 -10.73 5.60E-10 1.09E-07 membrane-associated ring finger (C3HC4) 3
ILMN_3940615 PUS7 -10.52 7.99E-10 1.52E-07 pseudouridylate synthase 7 homolog
ILMN_20544 GART -10.41 9.53E-10 1.76E-07 phosphoribosylglycinamide formyltransferase
ILMN_2480326 HSP90B1 -10.36 1.05E-09 1.88E-07 heat shock protein 90 kDa beta (Grp94), member 1
ILMN_5270367 CTSC -10.25 1.26E-09 2.20E-07 cathepsin C
ILMN_5420095 MYC -10.21 1.36E-09 2.34E-07 v-myc myelocytomatosis viral oncogene homolog
ILMN_4610180 PIK3C2B -10.20 1.38E-09 2.37E-07 phosphoinositide-3-kinase, class 2, beta polypeptide
ILMN_6450300 GEMIN4 -10.00 1.95E-09 3.27E-07 gem (nuclear organelle) associated protein 4
t, t-statistic; and FDR, false discovery rate
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Page 8 of 13with ALL [16] or cell-line models of ALL [13], we
applied parametric gene set enrichment analysis
(PGSEA) [28]. Comparing gene expression profiles from
multiple experiments is notoriously difficult and typi-
cally any true similarities are swamped by technical dif-
ferences in microarray vendor, normalization strategies
and analytical approach. By summarizing genes at the
gene set level (such as genes in the same pathway),
these technical differences are mitigated, allowing com-
parison of samples from multiple studies.
We performed PGSEA on the 6-8 hour samples from
the 3 studies, and then two-dimensional hierarchical
clustering to identify the relationships between the differ-
ent ALL models (Figure 2 and annotated in additional
file 3). This revealed considerable heterogeneity in the
molecular response to glucocorticoids in patients into at
least 2, and possibly 4 different groups (green bars, Figure
2), which may represent different modes of response to
glucocorticoids in patients. Relative to this inter-patient
heterogeneity, both cell lines (purple bars, Figure 2) and
Table 4 Genes regulated 24 hours following dexamethasone treatment
ProbeSet ID Gene t P FDR Definition
Upregulated
ILMN_3930687 FAM112A 6.67 1.32E-06 0.0091 family with sequence similarity 112, member A
ILMN_6620255 TRIM74 6.29 3.06E-06 0.0132 tripartite motif-containing 74
ILMN_4280113 NFKBIA 6.23 3.48E-06 0.0138 nuclear factor kappa B inhibitor, alpha
ILMN_2140136 EMR2 6.10 4.65E-06 0.0149 egf-like containing, mucin-like, hormone receptor-like 2
ILMN_7000397 ANKRD15 6.08 4.91E-06 0.0149 ankyrin repeat domain 15
Downregulated
ILMN_870524 HOXB8 -8.60 2.53E-08 0.0011 homeo box B8
ILMN_4830520 LOC144501 -6.72 1.19E-06 0.0091 hypothetical protein LOC144501
ILMN_6110332 ARHGAP19 -6.70 1.24E-06 0.0091 Rho GTPase activating protein 19
ILMN_2970619 ESPL1 -6.65 1.38E-06 0.0091 extra spindle pole bodies homolog 1
ILMN_3130541 CCNF -6.64 1.43E-06 0.0091 cyclin F
ILMN_4760577 CENPA -6.62 1.46E-06 0.0091 centromere protein A
ILMN_4810646 PIF1 -6.54 1.76E-06 0.0095 PIF1 5’-to-3’ DNA helicase homolog
ILMN_1070762 PSRC1 -6.40 2.38E-06 0.0114 proline/serine-rich coiled-coil 1
ILMN_4860703 LOC648695 -6.19 3.82E-06 0.0138 retinoblastoma binding protein 4
ILMN_1110538 INCENP -6.05 5.19E-06 0.0149 inner centromere protein antigens 135/155 kDa
t, t-statistic; and FDR, false discovery rate
Table 5 Genes regulated 48 hours following dexamethasone treatment
ProbeSet ID Gene t P FDR Definition
Upregulated
ILMN_6620255 TRIM74 6.30 3.01E-06 0.0089 tripartite motif-containing 74
Downregulated
ILMN_4810646 PIF1 -8.85 1.58E-08 0.0004 PIF1 5’-to-3’ DNA helicase homolog
ILMN_870524 HOXB8 -8.66 2.26E-08 0.0004 homeo box B8
ILMN_1450193 LGALS1 -8.57 2.66E-08 0.0004 lectin, galactoside-binding, soluble, 1 (galectin 1)
ILMN_4760577 CENPA -7.64 1.71E-07 0.0018 centromere protein A
ILMN_4730605 AURKA -7.47 2.42E-07 0.0021 aurora kinase A
ILMN_1500010 CDC20 -6.84 9.09E-07 0.0053 CDC20 cell division cycle 20 homolog
ILMN_4060064 HMMR -6.82 9.61E-07 0.0053 hyaluronan-mediated motility receptor
ILMN_2070408 MID1 -6.80 9.97E-07 0.0053 midline 1 (Opitz/BBB syndrome)
ILMN_2070288 MT1E -6.66 1.36E-06 0.0065 metallothionein 1E
ILMN_1070762 PSRC1 -6.60 1.55E-06 0.0067 proline/serine-rich coiled-coil 1
ILMN_150543 C20orf129 -6.46 2.12E-06 0.0077 chromosome 20 open reading frame 129
ILMN_5870193 FAM64A -6.45 2.14E-06 0.0077 family with sequence similarity 64, member A
ILMN_2810201 KIF14 -6.34 2.77E-06 0.0089 kinesin family member 14
ILMN_1050195 KIF20A -6.28 3.11E-06 0.0089 kinesin family member 20A
ILMN_3130541 CCNF -6.05 5.21E-06 0.0131 cyclin F
t, t-statistic; and FDR, false discovery rate
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Page 9 of 13xenografts (black bars, Figure 2) are remarkably reprodu-
cible; we anticipate that adding additional xenograft
models of ALL from distinct patients will mirror the het-
erogeneity of the patient from whom they were derived.
It is also evident that overall, glucocorticoid-treated
xenografts co-cluster with a group of 3 patients (B-ALL-
37, -38, and -40), all of whom had BCP-ALL and a good
early prednisolone response, with varied cytogenetics
(hyperploidy, t(12;21), and normal respectively). At more
relaxed clustering thresholds, the glucocorticoid-treated
xenografts cluster with 4 other patients with BCP-ALL
(B-ALL-24, -31, -33, and 43) and the cell lines.
We identified 5 clusters of gene sets with distinct
expression profiles, each behaving differently in the 3
models of ALL. Cluster 1 demonstrated the markedly
heterogeneous patterns seen in patient samples, with the
xenograft samples showing a pattern similar to 8 of the
patients; cluster 2 showed genesets that showed strong
enrichment in the cell line study, and included a num-
ber of genesets associated with cell proliferation; cluster
3 did not show any striking differences across the three
ALL models; cluster 4 showed genesets downregulated
in both xenografts and cell lines compared to the
patient samples, and included a number genesets
Figure 2 Parametric GSEA of combined top 100 glucocorticoid-induced gene sets with greatest variance from xenograft, patient and
cell line models. Hierarchical clustering with gene sets in rows, samples in columns (xenografts - black, patient - green, cell line - purple). Each
colour of each cell represents the Z-score (see legend). Boxes 1-5 represent defined clusters.
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Page 10 of 13associated with cell cycle progression, DNA/RNA repli-
cation and MYC; cluster 5 showed genesets strongly
downregulated in the xenograft and cell line models,
and included genesets associated with MYC and meta-
bolic processes, particularly catabolism and energy pro-
duction. In this limited comparison, it is clear that
glucocorticoid-induced gene expression patterns seen in
ALL are dependent on the experimental model, and that
the patterns derived from the xenograft model show a
greater similarity to patient-derived data than to cell
lines.
A search of the TRANSFAC database v8.3 [41] of
CoMoDis [42] identified GRE motifs (within 100 kb
either side of the gene) in only 25 (14.5%) of the top
173 upregulated genes at the 8 hour timepoint in this
study, and no GRE motifs were identified in the upregu-
lated genes at 24 or 48 hours. This supports accumulat-
ing evidence that glucocorticoids exert long-range
effects through very distal steroid receptor binding sites
[43]. Analysis of significantly differentially expressed glu-
cocorticoid-induced genes in an in vitro cell line study
[13] revealed a similar number of early response genes
after 6 hours of exposure (60 upregulated (t-stat > 10)
and 27 downregulated (t-stat < -10)) but a significantly
greater number of genes after 24 hours (593 upregulated
(t-stat > 10) and 782 downregulated (t-stat < -10)).
Interestingly, all but 2 of the genes upregulated at 6
hours remained significantly upregulated at 24 hours,
and 17 of the downregulated genes at 6 hours remained
downregulated at 24 hours. GRE motifs were identified
in 15 (25.0%) of the top 60 upregulated genes at 6
hours, and 87 (14.6%) of the top 593 genes at 24 hours.
The observed difference between the studies in gene
expression at later timepoints is consistent with continu-
ous rather than physiological glucocorticoid exposure. In
addition, in the cell line study, the GR (NR3C1) under-
goes highly significant early and sustained autoupregula-
tion, which in the continuous presence of ligand drives
downstream gene expression. In contrast, in the xeno-
graft model minimal GR upregulation is seen at the
early timepoint but no significant change in GR expres-
sion is seen at either of the later timepoints.
Given the good statistical power observed in Figure
1A, we proceeded to determine whether we could use
fewer replicates and still identify a majority of the differ-
entially expressed genes. Replicate analysis (Figure 3)
revealed that at the 8 hour dexamethasone-treated time-
point, a dataset with high signal and differential expres-
sion, using data from any 3 randomly chosen biological
replicates instead of 4 resulted in excellent recovery
scores of > 0.9. That is, on average, 90% of the differen-
tially expressed genes identified from all 4 samples were
also identified in any combination of 3 arrays. At 24
hours, a timepoint with less signal, the average recovery
score was 0.85 with 3 replicates, but was more variable
than at 8 hours. Using just 2 biological replicates
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Figure 3 Recovery scores at 8 hours and 24 hours when randomly selecting all combinations of 3 replicates (3rep) or 2 replicates
(2rep) from the set of 4 biological replicates. The Recovery Score represents the proportion of differentially expressed genes from all 4
replicates recovered when using fewer replicates.
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Page 11 of 13recovered 88% of the list of differentially expressed
genes at 8 hours, which dropped to 14% at 24 hours.
This confirms that the 8 hour time point has the stron-
gest signal, which is reproducible across different sub-
sets of biological replicates. We recommend using a
minimum of 3 biological replicates, since fewer repli-
cates destabilized our ability to identify differentially
expressed genes. This has important considerations for
experimental design, and has significant implications on
cost and animal numbers.
Conclusions
We conclude that the NOD/SCID ALL xenograft mouse
model provides biologically relevant insights into gluco-
corticoid-induced gene expression, in a consistent,
reproducible and clinically relevant model system. We
have demonstrated that the 8 hour timepoint provides
the highest number of significantly differentially
expressed genes, that time-matched controls are redun-
dant and excellent recovery scores can be obtained with
3 replicates. We have thus established the optimal
experimental design, with subsequent important impli-
cations for costs and animal numbers.
Additional material
Additional file 1: metaGSEA of genesets 8 hours after treatment
with dexamethasone. metaGSEA of top 100 up- and down-regulated
genesets identified by Gene Set Enrichment Analysis (GSEA) 8 hours after
treatment with dexamethasone.
Additional file 2: metaGSEA of genesets 24 hours after treatment
with dexamethasone. metaGSEA of top 100 up- and down-regulated
genesets identified by Gene Set Enrichment Analysis (GSEA) 24 hours
after treatment with dexamethasone.
Additional file 3: Annotated pGSEA comparing glucocorticoid-
induced genesets in xenograft, cell line and patient datasets.
Hierarchical cluster by parametric Gene Set Enrichment Analysis (PGSEA)
of the top 100 genesets with the greatest variance across three models
(xenograft in vivo, cell line in vitro, patient in vivo) of glucocorticoid-
induced gene expression in ALL, with annotation of the gene sets.
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